← FDA DRUG APPROVALS

FDA ANDA · ANDA073462

TOLMETIN SODIUM

Sponsor: CHARTWELL RX

APPLICATION
ANDA073462
TYPE
ANDA
ORIGINAL APPROVAL
1992-04-30
LATEST ACTION
2024-11-21
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Discontinued

Products

TOLMETIN SODIUMDiscontinued
TOLMETIN SODIUM EQ 400MG BASE · CAPSULE · ORAL

Approval history

2024-11-21Labeling · Supplement 7 · standardAP
2021-04-28Labeling · Supplement 6 · standardAP
2021-04-05Labeling · Supplement 5 · standardAP
2016-05-09Labeling · Supplement 4 · standardAP
2001-05-09Manufacturing (CMC) · Supplement 3AP
2001-04-14Manufacturing (CMC) · Supplement 2AP
1994-01-24Manufacturing (CMC) · Supplement 1AP
1992-04-30OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →